Company
TECregen
The Time for Regenerative Immune Therapeutics Is Now
Also known as TECregen AG
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Basel, Switzerland
- Founded
- 2023
- Legal name
- TECregen AG
Claim, correct or request removal
Record updated 28 September 2026
About
At TECregen, we believe that precision-engineered thymopoietics, designed to regenerate the thymus and restore immune balance, have the potential to redefine how we treat immune decline, cancer, and inflammatory disease.
Funding snapshot
- Latest round
- Seed2026-01-08
Funding rounds
- Seed
- 2026-01-08
Loading relationship preview